Compare ASYS & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASYS | NKTX |
|---|---|---|
| Founded | 1981 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.5M | 132.8M |
| IPO Year | 2006 | 2020 |
| Metric | ASYS | NKTX |
|---|---|---|
| Price | $13.19 | $2.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $13.25 |
| AVG Volume (30 Days) | 271.8K | ★ 674.7K |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $79,364,000.00 | N/A |
| Revenue This Year | $2.82 | N/A |
| Revenue Next Year | $18.75 | N/A |
| P/E Ratio | $1,295.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.20 | $1.31 |
| 52 Week High | $18.59 | $2.81 |
| Indicator | ASYS | NKTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.47 | 58.17 |
| Support Level | $11.60 | $1.95 |
| Resistance Level | $13.26 | $2.74 |
| Average True Range (ATR) | 0.74 | 0.19 |
| MACD | 0.11 | 0.00 |
| Stochastic Oscillator | 59.17 | 59.84 |
Amtech Systems Inc provides equipment, consumables and services for semiconductor device packaging, wafer production and device fabrication. Its products are used to fabricate and package GPUs for AI applications, SiC and Si power devices, and other optical, analog and digital devices, and are sold to semiconductor packaging, electronic assembly and device fabrication companies. It operates through two segments: Thermal Processing Solutions, which includes conveyorized reflow equipment, high-temperature conveyorized furnaces and diffusion furnaces with maximum revenue; and Semiconductor Fabrication Solutions, which includes consumables, equipment and services for wafer polishing, dicing and cleaning. The majority of revenue is derived from the United States.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.